Exercise of share options and Directors’ dealings

Mar 6, 2014

Advanced Medical Solutions Group plc
(“AMS” or the “Group”)

HomeRNS NewsDirector ShareholdingExercise of share options and Directors’ dealings
RNS Number : 7389B
Advanced Medical Solutions Grp PLC
06 March 2014
 



6 March 2014

 

Advanced Medical Solutions Group plc

(“AMS” or the the “Company”)

 

Exercise of share options and Directors’ dealings

 

Winsford, UK:Advanced Medical Solutions Group plc (AIM:AMS), the global medical technology company, today announces that Chris Meredith, Chief Executive Officer, has today sold a total of 643,250 ordinary shares of 5p each (“Ordinary Shares”) at 114 pence per share. These shares come from a combination of the exercise of certain share incentive schemes and existing Ordinary Shares. Separately, Mr Meredith’s SIPP has today acquired 87,719 Ordinary Shares at 114 pence per share.

 

As a result of these transactions, Mr Meredith’s beneficial interest in Ordinary Shares has increased from 1,142,275 to 1,182,938.

 

A summary of Mr Meredith’s beneficial interest in Ordinary Shares and Ordinary Shares under incentive schemes is summarised in the table below.

 

 

Number prior to transaction

Number exercised

Shares sold

SIPP purchase

Resultant interest

Ordinary Shares

1,142,275

–

47,056

87,719

1,182,938

Long Term Incentive Plan

1,309,293

514,778

514,778

–

794,515

Deferred Share Bonus Plan

99,325

81,416

81,416

–

17,909

 

– End –

 

For further information, please visit www.admedsol.com or contact:

 

Advanced Medical Solutions Group plc

Tel: +44 (0) 1606 545508

Mary Tavener, Group Finance Director




Investec Bank PLC (NOMAD & Broker)

Tel: +44 (0) 20 7597 5970

Daniel Adams


 


This information is provided by RNS
The company news service from the London Stock Exchange
 

END

 
 

RDSEAKDKELPLEFF

For further information, please contact:

Advanced Medical Solutions Group plc

Tel: 44 (0) 1606 545508

Chris Meredith, Chief Executive Officer

Eddie Johnson, Chief Financial Officer

Michael King, Investor Relations

Consilium Strategic Communications

Tel: 44 (0) 20 3709 5700

Matthew Neal / Lucy Featherstone

Investec Bank PLC (NOMAD & Broker)

Tel: 44 (0) 20 7597 5970

Gary Clarence / David Anderson

HSBC Bank PLC (Broker)

Tel: 44 (0) 20 7991 8888

Sam McLennan / Joe Weaving / Stephanie Cornish

About Advanced Medical Solutions Group plc

AMS is a world-leading independent developer and manufacturer of innovative tissue-healing technology, focused on quality outcomes for patients and value for payers. AMS has a wide range of surgical products including tissue adhesives, sutures, haemostats, internal fixation devices and internal sealants, which it markets under its brands LiquiBand®, RESORBA®, LiquiBandFix8® and Seal-G®. AMS also supplies wound care dressings such as silver alginates, alginates and foams through its ActivHeal® brand as well as under white label. Since 2019, the Group has made five acquisitions: Sealantis, an Israeli developer of innovative internal sealants; Biomatlante, a French developer and manufacturer of surgical biomaterials, Raleigh, a leading UK coater and converter of woundcare and bio-diagnostics materials, AFS Medical, an Austrian specialist surgical business and Connexicon, an Irish tissue adhesives specialist.

AMS's products, manufactured in the UK, Germany, France, the Netherlands, the Czech Republic and Israel, are sold globally via a network of multinational or regional partners and distributors, as well as via AMS's own direct sales forces in the UK, Germany, Austria, the Czech Republic and Russia. The Group has R&D innovation hubs in the UK, Ireland, Germany, France and Israel. Established in 1991, the Group has more than 800 employees. For more information, please see admedsol.com.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com. RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.